BackCorcept Therapeutics Incorporated Overview

Corcept Therapeutics Incorporated Current Assets

Track Corcept Therapeutics Incorporated's current assets ($440M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$439.68M
↓ 0.78% YoYΔ $-3.44M vs prior year quarter

Peer trimmed avg / median

Loading

Corcept Therapeutics Incorporated Current Assets History

Loading

Corcept Therapeutics Incorporated vs. peers: Current Assets Comparison

Loading

Corcept Therapeutics Incorporated Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Corcept Therapeutics Incorporated (0I3Q.L) FAQ

Corcept Therapeutics Incorporated's current assets stands at $440M as of June 2026. That compares with $440M in the prior-year period — down 0.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Corcept Therapeutics Incorporated reported $440M in current assets versus $440M a year earlier — a 0.8% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $440M in the prior-year period — down 0.8% year over year. Sustained growth in current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Corcept Therapeutics Incorporated's current assets evolved across reporting periods, while the comparison chart places 0I3Q.L next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current assets is commonly used to spot outliers. Corcept Therapeutics Incorporated's reading of $440M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.